CBD reshapes lipid profiles in Alzheimer’s-relevant nerve cells
Lipidomic Evidence for Cannabidiol-Induced Remodeling of Cellular Lipid Composition in SH-SY5Y Cells.
AI Summary
This abstract-based summary describes a cell study asking whether cannabidiol (CBD) changes cellular lipid composition in SH-SY5Y human neuroblastoma cells. Researchers used targeted lipidomics to compare wild-type cells with cells engineered to express the Alzheimer’s disease-associated APP Swedish mutation. The abstract does not report the sample size, treatment duration, comparator details beyond these cell models, or quantitative effect sizes.
CBD produced a broad, class-specific remodeling of the cells’ lipidome. Diacyl and ether-linked phosphatidylcholines increased overall, while many less-unsaturated species rose and several highly polyunsaturated ether-linked species declined. Lysophosphatidylcholines, total sphingomyelin, free carnitine, and most measured acylcarnitines also decreased. Similar phosphatidylcholine changes occurred in APP Swedish mutation-expressing cells, linking the response to a lipid context relevant to Alzheimer’s disease. However, this laboratory study cannot establish that CBD improves Alzheimer’s disease, protects neurons, or produces the same effects in animals or humans; it also does not establish the functional consequences of the lipid changes. This is an abstract-based summary, not a full-text review.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.